AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8058153 — intervention group
Group type: EXPERIMENTAL
Intervention: DBD plus BCNU
Number of subjects: 255
Study 3049968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (patient involvement in medical decision making)
Number of subjects: 59
Study 3049968 — intervention group
Group type: COMPARATOR
Intervention: Control (standard educational materials)
Number of subjects: 59
Study 29795579 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-based retention strategies (message content and delivery methods)
Number of subjects: 1536
Study 29795579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1536
Study 27528067 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic blockade (trimethaphan 4 mg/min IV)
Number of subjects: 14
Study 27528067 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (10, 30, and 50 μg/min)
Number of subjects: 14
Study 27528067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1, 2, and 3 μg/min)
Number of subjects: 14
Study 27528067 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic blockade (trimethaphan)
Number of subjects: 14
Study 27528067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (after autonomic blockade)
Number of subjects: 14
Study 24734184 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU of oxytocin in 1000 mL Ringer's solution and two placebo tablets
Number of subjects: 400
Study 24734184 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg oral misoprostol (as two tablets) and 2 mL normal saline in 1000 mL Ringer's solution
Number of subjects: 400
Study 22465648 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 101
Study 22465648 — intervention group
Group type: COMPARATOR
Intervention: Anterior approach
Number of subjects: 101
Study 20456355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg TID for 3 days) in combination with idarubicin
Number of subjects: 41
Study 20456355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (TID for 14 days) in combination with idarubicin
Number of subjects: 41
Study 20456355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (TID for 3 days)
Number of subjects: 41
Study 20456355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat and idarubicin
Number of subjects: 41
Study 18593524 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA DR soft gelatin capsule (500 mg), fasting
Number of subjects: 36
Study 18593524 — intervention group
Group type: COMPARATOR
Intervention: Divalproex sodium DR tablet (500 mg), fasting
Number of subjects: 36
Study 18593524 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA DR soft gelatin capsule (500 mg), non-fasting
Number of subjects: 36
Study 16202734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg every 3 hours)
Number of subjects: 132
Study 16202734 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic PGF2alpha (carboprost 1.5 mg)
Number of subjects: 132
Study 11863117 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTX (110 mg/m2) plus LCV (200 mg/m2) and 5-FU (500 mg/m2)
Number of subjects: 382
Study 11863117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 9182114 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 300 mg as a single dose on admission
Number of subjects: 160
Study 9182114 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg bd for three days
Number of subjects: 160
Study 9182114 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg as a single dose
Number of subjects: 160
Study 9182114 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control group)
Number of subjects: 160
Study 9182114 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose norfloxacin treatment
Number of subjects: 160
Study 2161578 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy
Number of subjects: 0
Study 2161578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral + intramuscular estrogens
Number of subjects: 0
Study 2161578 — intervention group
Group type: COMPARATOR
Intervention: Single drug intramuscular estrogens
Number of subjects: 0
Study 6256791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1 ml/kg)
Number of subjects: 2
Study 6256791 — intervention group
Group type: COMPARATOR
Intervention: Marijuana (15 mg)
Number of subjects: 2
Study 31822443 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-MLPA
Number of subjects: 183
Study 30768180 — intervention group
Group type: EXPERIMENTAL
Intervention: TVV+ isolates
Number of subjects: 355
Study 30768180 — intervention group
Group type: COMPARATOR
Intervention: TVV- negative isolates
Number of subjects: 355
Study 28358594 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage-colony stimulating factor (GM-CSF)
Number of subjects: 132
Study 28358594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 25271206 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg empagliflozin
Number of subjects: 825
Study 25271206 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg empagliflozin
Number of subjects: 825
Study 25271206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 23033846 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (16-week program including one home-visit, five group and five individual sessions)
Number of subjects: 80
Study 23033846 — intervention group
Group type: COMPARATOR
Intervention: Control group (information provision)
Number of subjects: 80
Study 22131908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc alone (10 mg)
Number of subjects: 612
Study 22131908 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐nutrients without zinc
Number of subjects: 612
Study 22131908 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐nutrients with zinc
Number of subjects: 612
Study 22131908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 22131908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 612
Study 22131908 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐nutrients
Number of subjects: 612
Study 22131908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc deficiency
Number of subjects: 612
Study 19184556 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-augmentation group (n = 32)
Number of subjects: 67
Study 17544652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense biweekly therapy with doxorubicin and docetaxel
Number of subjects: 436
Study 17544652 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response by palpation after the 3rd cycle
Number of subjects: 436
Study 17544652 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response by palpation for pathologic complete response (pCR)
Number of subjects: 436
Study 15001462 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 9
Study 15001462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11528551 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-based induction
Number of subjects: 471
Study 11528551 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin-based induction
Number of subjects: 471
Study 11528551 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin
Number of subjects: 471
Study 11528551 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cytarabine and mitoxantrone (HAM)
Number of subjects: 471
Study 11528551 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 471
Study 11528551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotoxicity assessment
Number of subjects: 471
Study 10433439 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) surgery
Number of subjects: 100
Study 10433439 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient department
Number of subjects: 100
Study 7630685 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet subsidy program ($10 helmets) and educational program
Number of subjects: 1415
Study 7630685 — intervention group
Group type: COMPARATOR
Intervention: Control areas (no intervention)
Number of subjects: 1415
Study 7630685 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet subsidy program
Number of subjects: 1415
Study 7630685 — intervention group
Group type: EXPERIMENTAL
Intervention: All income areas
Number of subjects: 1415
Study 7630685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income areas
Number of subjects: 1415
Study 7630685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-income areas
Number of subjects: 1415
Study 2197772 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 93
Study 2197772 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 93
Study 19506 — intervention group
Group type: EXPERIMENTAL
Intervention: Single graded intramuscular doses of morphine test
Number of subjects: 0
Study 19506 — intervention group
Group type: COMPARATOR
Intervention: Single graded intramuscular doses of morphine standard
Number of subjects: 0
Study 31666832 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose 1000 mg orally for two days prior to hysterosalpingography
Number of subjects: 66
Study 31666832 — intervention group
Group type: COMPARATOR
Intervention: Placebo drug similar in size to evening primrose three days prior to hysterosalpingography
Number of subjects: 66
Study 28823809 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision Saw (PS)
Number of subjects: 58
Study 28823809 — intervention group
Group type: COMPARATOR
Intervention: Sagittal Saw (SS)
Number of subjects: 58
Study 28823809 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Surgery Time
Number of subjects: 58
Study 25687560 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed video-based 1-2-3 Magic parenting program (n=43)
Number of subjects: 84
Study 25687560 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=41)
Number of subjects: 84
Study 23160873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (BT)
Number of subjects: 0
Study 23160873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0
Study 23160873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pelvic floor rehabilitation (CPFR)
Number of subjects: 0
Study 23160873 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (DT)
Number of subjects: 0
Study 21371314 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative treatment (further treatment from general practitioner and physical therapist)
Number of subjects: 0
Study 21371314 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 0
Study 20066882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study 16757722 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway treatment in nursing homes (oral antimicrobials, portable chest radiographs, oxygen saturation monitoring, rehydration, close monitoring by a research nurse)
Number of subjects: 680
Study 16757722 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 680
Study 16757722 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway treatment
Number of subjects: 680
Study 14707554 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88 (nitric oxide synthase inhibitor)
Number of subjects: 312
Study 14707554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 312
Study 14707554 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88
Number of subjects: 312
Study 14707554 — intervention group
Group type: COMPARATOR
Intervention: 546C88 and Placebo
Number of subjects: 312
Study 11334121 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention consisting of two 2-hour group sessions followed by 1-2 individual sessions administered by a nurse and a physiotherapist, emphasizing self-management
Number of subjects: 78
Study 11334121 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 78
Study 11334121 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary outpatient consultation care)
Number of subjects: 78
Study 9013165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar probe
Number of subjects: 21
Study 9013165 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 21
Study 9013165 — intervention group
Group type: COMPARATOR
Intervention: Prior medical therapy
Number of subjects: 21
Study 8525817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 10 mg daily for 6 weeks
Number of subjects: 90
Study 8525817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg daily for 6 weeks
Number of subjects: 90
Study 8525817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2691121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (200 mg p.o.)
Number of subjects: 0
Study 30526266 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercise program based on National Academy of Sport Medicine guidelines
Number of subjects: 96
Study 30526266 — intervention group
Group type: COMPARATOR
Intervention: Usual training routine (Control)
Number of subjects: 96
Study 31446638 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN-based therapy
Number of subjects: 91
Study 31446638 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HBV RNA (cut-off 2.0 log10 copies/mL)
Number of subjects: 91
Study 31446638 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV RNA level ≥ 2 log10 copies/mL at week 12 during therapy
Number of subjects: 91
Study 28138234 — intervention group
Group type: EXPERIMENTAL
Intervention: High inspiratory pressure settings
Number of subjects: 10
Study 28138234 — intervention group
Group type: EXPERIMENTAL
Intervention: High breathing frequency
Number of subjects: 10
Study 28138234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure, low-frequency setting
Number of subjects: 10
Study 28138234 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency settings
Number of subjects: 10
Study 27071273 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoshuantong capsule plus Aspirin
Number of subjects: 696
Study 27071273 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 696
Study 23698556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraception (OC) use
Number of subjects: 28
Study 23698556 — intervention group
Group type: COMPARATOR
Intervention: Menstrual cycle phase
Number of subjects: 28
Study 22078152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg TID for 4 weeks, then 100 mg TID for 12 weeks)
Number of subjects: 55
Study 22078152 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (2.5 mg TID for 4 weeks, then 5 mg TID for 12 weeks)
Number of subjects: 55
Study 19909879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Number of subjects: 383
Study 19909879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg
Number of subjects: 383
Study 19909879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose group of Ambrisentan
Number of subjects: 383
Study 19909879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 383
Study 16510054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 40
Study 16510054 — intervention group
Group type: COMPARATOR
Intervention: Injection of 0.5 cc lidocaine 1% plus methylprednisolone acetate (Depo-Medrol) 40 mg
Number of subjects: 40
Study 15131559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation and prevention program (CRPP) - 2-hour twice-weekly exercise program for 8 weeks
Number of subjects: 269
Study 15131559 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 269
Study 15131559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation and prevention program (CRPP)
Number of subjects: 269
Study 11286464 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin (EPI), leucovorin (LV) and 5‐fluorouracil (5‐FU) on days 1‐3 every 3 weeks for 7 months
Number of subjects: 137
Study 11286464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 137
Study 9587651 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (100 mg or 500 mg intravenously)
Number of subjects: 14
Study 8518024 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 100 mg orally twice a day for 12 months
Number of subjects: 856
Study 8518024 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy on pelvis
Number of subjects: 856
Study 8518024 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus MPA
Number of subjects: 856
Study 8518024 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy on pelvis and para-aortic nodes
Number of subjects: 856
Study 3312857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Number of subjects: 22
Study 3312857 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 22
Study 31617138 — intervention group
Group type: EXPERIMENTAL
Intervention: Clubhouse Model of Psychosocial Rehabilitation
Number of subjects: 56
Study 31617138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 29228247 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8477 100 mg
Number of subjects: 25
Study 29228247 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 25
Study 29228247 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8477 (all doses)
Number of subjects: 25
Study 29228247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27861191 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended-release (ER) 40-120 mg/day
Number of subjects: 0
Study 27861191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26254464 — intervention group
Group type: EXPERIMENTAL
Intervention: Double edge closure technique (DE group)
Number of subjects: 120
Study 26254464 — intervention group
Group type: COMPARATOR
Intervention: Usual pericostal sutures (PC group)
Number of subjects: 120
Study 23363394 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional endoscopy method
Number of subjects: 163
Study 23363394 — intervention group
Group type: COMPARATOR
Intervention: Indigo carmine contrast (IC) method
Number of subjects: 163
Study 20808132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 52
Study 20808132 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 52
Study 20808132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19057612 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant lung lavage (SLL)
Number of subjects: 13
Study 19057612 — intervention group
Group type: COMPARATOR
Intervention: Bolus surfactant treatment
Number of subjects: 13
Study 16519552 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% bimatoprost ophthalmic solution once daily
Number of subjects: 0
Study 16519552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analyses of bimatoprost
Number of subjects: 0
Study 12928714 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 20
Study 12928714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10921652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg strength training program for the dominant leg
Number of subjects: 20
Study 10921652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg strength training program for the nondominant leg
Number of subjects: 20
Study 10921652 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal activities)
Number of subjects: 20
Study 8940325 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (higher disease prevalence, 60% prevalence of PE)
Number of subjects: 6
Study 8940325 — intervention group
Group type: COMPARATOR
Intervention: Group B (lower disease prevalence, 20% prevalence of PE)
Number of subjects: 6
Study 8259720 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm bath
Number of subjects: 30
Study 8259720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 30
Study 3976629 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulated bunting
Number of subjects: 0
Study 3976629 — intervention group
Group type: COMPARATOR
Intervention: Insulated hat
Number of subjects: 0
Study 3976629 — intervention group
Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 0
Study 30496407 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically higher BMI (each standard deviation)
Number of subjects: 750
Study 30496407 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score of 92 BMI SNPs
Number of subjects: 750
Study 30496407 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO SNP rs1421085 with BMI in women with PCOS
Number of subjects: 750
Study 29587688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 31
Study 29587688 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 31
Study 26934963 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Anastomosis (VA) group with a detailed rat anastomosis script
Number of subjects: 36
Study 26934963 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Relaxation (VR) group with a relaxation script
Number of subjects: 36
Study 26934963 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with no mental rehearsal script
Number of subjects: 36
Study 24812896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongfu Mixture (TM)
Number of subjects: 54
Study 24812896 — intervention group
Group type: COMPARATOR
Intervention: Control (routine therapy)
Number of subjects: 54
Study 22187386 — intervention group
Group type: EXPERIMENTAL
Intervention: Velotron Racermate™ cycle ergometer
Number of subjects: 40